Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Diabetes: later-stage trial registry
86 of 342 indexed Diabetes trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #19 of 28,707 conditions by registered trial count.
342 US clinical trials · 86 currently recruiting · #19 of 28,707 conditions by registered trial count
Diabetes: 342 US clinical trials tracked, 86 recruiting.
Diabetes is the subject of 342 registered US clinical trials on ClinicalTrials.gov, 86 of them currently open to new participants. 55 are in Phase 3-4 (later-stage) and 36 in Phase 1-2 (earlier-stage). The most active sponsor is Novo Nordisk A/S, running 41 of these trials.
Enrollment posture brief
Registry condition diabetes
OPEN 86 | RECR 25% | LATE 55 | EARLY 36 | RANK #19 | SPON 41
Volume-matched condition peers
Nearest open-share peer: Low Back Pain (25% recruiting · 123 trials)
Diabetes lists 86 open slots (25% of 342 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Diabetes on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Diabetes is recruiting below its size-band peers.
86 of 342 indexed trials (25.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Diabetes trials is spread across many organizations.
Novo Nordisk A/S accounts for 41 of 342 trials (12%). 161 distinct sponsors appear on at least one study for this condition label.
-
Typical Diabetes enrolment sits around 150 participants.
Median target enrolment is 150 among the 339 trials that report a genuine target (sentinel values excluded). 144 of those (42.5%) plan for fewer than 100 participants.
-
Diabetes research is mostly interventional.
263 interventional and 79 observational studies make up this index (76.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
342 total, page 4 of 7
Evaluation of a Noninvasive Diabetes Screening Device in Subjects at Risk for Diabetes
VeraLight
NCT01080157
Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes
Novo Nordisk A/S
NCT00104182
Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
Novo Nordisk A/S
NCT01076647
Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes
Novo Nordisk A/S
NCT01045447
Healthy Eating and Active Living Taught at Home
Washington University School of Medicine
NCT01567033
Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin
Novo Nordisk A/S
NCT01046110
The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy
Novo Nordisk A/S
NCT01618162
Healthy.io Method Comparison & User Performance Study
Healthy.io
NCT02785445
DHS MIND Metabolomics
Wake Forest University Health Sciences
NCT03975309
Wound Assessment Using Spectral Imaging US
SpectralMD
NCT05415683
The ABC Planning Study: Diabetes and Cardiovascular Risks in Primary Care
The University of Texas Health Science Center at San Antonio
NCT00223340
The Health Access and Recovery Peer Program
Emory University
NCT01725815
The GoodNEWS Lifestyle Enhancement Program
University of Texas Southwestern Medical Center
NCT00669630
Therapeutic Stockings to Prevent Foot Ulcers
University of Texas Southwestern Medical Center
NCT01221194
Evaluation of a Ascensia ONYX NEXT Investigational Blood Glucose Monitoring System
Ascensia Diabetes Care
NCT02390167
Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S
NCT01364428
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
Novo Nordisk A/S
NCT01835431
Harnessing Health IT for Self-Management Support and Medication Activation in a Medicaid Health Plan
University of California, San Francisco
NCT00683020
Feasibility and Impact of "ABCs of Diabetes" Self-Management Education Program at an Urban Public Library
Medstar Health Research Institute
NCT00822471
Enhanced Quality in Primary Care for Elders With Diabetes and Dementia
NYU Langone Health
NCT03723707
A Helping Hand Among Low-Income Patients
University of Southern California
NCT02147522
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
Novo Nordisk A/S
NCT01664247
Improving Diabetes Efforts Across Language and Literacy (IDEALL)
Agency for Healthcare Research and Quality (AHRQ)
NCT00214474
Growing Resilience in Wind River Indian Reservation
University of Wyoming
NCT02672748
Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic Pain
Lexicon Pharmaceuticals
NCT04455633
Family Genetics Health Education and Healthy Behaviors
National Human Genome Research Institute (NHGRI)
NCT01498276
Effectiveness of Patient-centered Community Health Worker Support to Help Patients Control Chronic Disease
University of Pennsylvania
NCT01900470
Men Together Making a Difference: Health Promotion for Black Men
University of Pennsylvania
NCT02572414
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
Novo Nordisk A/S
NCT03086330
Racial/Ethnic Differences in Trust/Mistrust and Its Effect on Diabetes Outcomes
US Department of Veterans Affairs
NCT00383110
Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes
Novo Nordisk A/S
NCT00097877
Multicenter Worksite Nutrition Study
Physicians Committee for Responsible Medicine
NCT01224548
Evaluation of Extended Wear Infusion Set (EWIS) in Patients With Type 1 Diabetes
Medtronic Diabetes
NCT04113694
Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes
VA Office of Research and Development
NCT01855399
Diabetes CKD Lifestyle Technology Study
NYU Langone Health
NCT02266823
Sunshine 2 Study for Women With Diabetes
Loyola University
NCT01904032
Preventing Depression Recurrence in Diabetes
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00374426
Self-Monitoring of Blood Glucose Study#1: The Ability of People With Diabetes to Use OneTouch(R) Ultrasmart(tm)
LifeScan
NCT00333853
Improving Adherence to Prescribing Guidelines for Cholesterol Lowering in Hospitalized Diabetic Patients
Washington University School of Medicine
NCT01113099
Improving Insulin Therapy With Enhanced Care Management
US Department of Veterans Affairs
NCT00320112
Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics
Novo Nordisk A/S
NCT00773279
Peer-Led Self-Management Support in "Real World" Clinical and Community Settings
University of Michigan
NCT01517919
A Study Comparing Skin Fluorescence to Coronary Artery Calcification
VeraLight
NCT00895427
Food Intake and Appetite in the Children of Mothers With Diabetes
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00339313
Can Group Visits Improve Outcomes of Veterans With Diabetes
US Department of Veterans Affairs
NCT00286741
Framingham State Food Study
Boston Children's Hospital
NCT02068885
Lifestyle Intervention in Overweight and Obese Pregnant Hispanic Women
University of Massachusetts, Amherst
NCT01868230
Cocoa, Polyphenols, and the Kidney in Healthy Subjects and in Subjects With Hypertension and Diabetes Mellitus
Brigham and Women's Hospital
NCT00639665
Tailored Approaches to Reduce Distress and Improve Self-Management for Veterans With Diabetes
VA Office of Research and Development
NCT04587336
A Study of the Function of Hormones Present In Taste Buds
National Institute on Aging (NIA)
NCT00233298
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 23 |
| Phase 2 | 13 |
| Phase 3 | 37 |
| Phase 4 | 18 |
Top Sponsors
Named interventions
Most-linked intervention names on Diabetes records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Diabetes trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Diabetes page
342 registered trials, 86 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 86 Diabetes trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novo Nordisk A/S sponsors the most Diabetes trials on record, review their full trial history before evaluating a specific study. See Novo Nordisk A/S's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Diabetes condition card totals 342 registered trials; most-linked intervention insulin degludec; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.